ArticleJournal of hepatocellular carcinoma2025

Early PIVKA-II Response Associated with Treatment Efficacy and Survival Outcomes for Patients with Advanced Hepatocellular Carcinoma Receiving Immune Checkpoint Inhibitors and Targeted Therapy.

Zheng-Kang Fang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.